drugset / Trial / NCT02271893

Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management

NCT02271893

RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.

Timeline

Start
2014-11-25
Primary completion
2017-10-26
Completion
2022-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown 90 mg